ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
 

논문 상세

Home > 논문 상세
  • P-ISSN 1010-0695
  • E-ISSN 2288-3339

銀翹散과 Ciprofloxacin 倂用이 호기성 Gram(+) 細菌株에 대한 試驗管內 抗菌力에 미치는 影響

Effects of In Vitro Synergism of Eunkyo-san and Ciprofloxacin against 9 Strains of Aerobic Gram(+) Bacteria

대한한의학회지 / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2005, v.26 no.1, pp.195-205
신창호 (대구한의대한의학과)
송광규 (대구한의대한의학과)
박미연 (대구한의대한의학과)
최해윤 (대구한의대한의학과)
김종대 (대구한의대한의학과)
  • 다운로드 수
  • 조회수

Abstract

objectives & Methods : In order to evaluate the in vitro synergic effect of Eunkyo-san which was a traditional poly-herbal formula has been used in the treatment of respiratory diseases in oriental medicine, with quinolone antibiotics, ciprofloxacin(CPFX) the minimal concentration(MIC), MIC50 and MIC90 of single use of quinolones and concomitant treatment with Eunkyo-san against 9 strains of gram positive bacteria. Results : In the case of aerobic gram positive bacteria, the MIC, MIC50 and MIC90 against Staphylococcus aureus, Staphylococcus aureus smith, Staphylococcus epidermidis, Streptococcus pyogens, Streptococcus pneumoniae Type I, Type II and Type III was significantly decreased in concomitant treated groups with Eunkyo-san compared to those of single treated groups of CPFX, respectively. However, no significant changes were demonstrated against Bacillus subtilis and Enterococcus faecalis. Conclusion : The in vitro antibacterial activity of CPFX were increased against some strains of gram positive strains, especially, pneumococcus such as Staphylococcus, Streptococcus by concomitant use of Eunkyo-san.

keywords
Quinolones, Ciprofloxacin(CPFX), Aerobic Gram positive bacteria, Eunkyo-san(銀翹散), Quinolones, Ciprofloxacin(CPFX), Aerobic Gram positive bacteria, Eunkyo-san(銀翹散)


참고문헌

1

(2000) natural history or natural selection,

2

(2001) utilization in renal and urogenital tract infections. Med Klin. 2001,

3

(2001) Paladino JA. Is more than one quinolone needed in clinical practice,

4

(1999) Hooper DC. Mode of action of fluoroquinolones. Drugs. ,

5

(2001) Hooper DC. Mechanisms of action of antimicrobials focus on fluoroquinolones. Drugs. 2001,

6

(2001) 麻黃潤肺湯이 ovalbumin으로 誘發된 mouse의 喘息에 미치는 影響,

7

(2003) 麻黃潤肺湯과 rufloxacin 倂用이 Gram(+) 細菌柱에 대한 試驗管內 抗菌力에 미치는 影響,

8

(2003) 麻黃潤肺湯과 ciproxacin 倂用이 Gram(+) 細菌柱에 대한 試驗管內 抗菌力에 미치는 影響,

9

(2001) Perea E. Differences between two new quinolones and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae. Chemotheraphy. 2001,

10

(2001) Cosar G. Investigation of synergism of moripenem and ciprofloxacin against Pseudomonas aeruginosa and Actinetobacter strains isolated from intensive care unit infections. Scand J Infect Dis. 2001,

11

(1998) Andrews JM. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens. J Chemother. 1998,

12

(2001) Arai S. In vitro activities of moxifloxacin and other fluoroquinolones against Myoplasma pneumoniae. Antimicrob Agents Chemother. 2001,

13

(1996) Seibert G. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoro- quinolones,

14

Balfour JA. Ciprofloxacin. A review of its pharmaco- logical profile and therapeutic use in the elderly. Drugs Aging. 1994,

15

Fass RJ. Ciprofloxacin. Best use of this new broad-spectrum antibiotic. Postgrad Med. 1990,

16

(2001) Chrysanthopoulos K. Evaluation of cardiac subacute- toxicity of ciprofloxacin in rats using serum biochemical parameters. Arzneimittelforshung. 2001,

17

(2001) Escutia B. Ciprofloxacin-induced vasculitis with cutaneous and renal involvement. Nefrologia. 2001,

18

(2001) Tschulenk W. Effects of enrofloxacin and ciprofloxacin hydrochloride on canine and equine chondrocytes in culture. Am J Vet Res.. 2001,

19

(2000) Hannafin JA. The effect of ciprofloxacin on tendon,

20

(2001) John JF Jr. A sequence variant of Staphylococcus hominis with a high prevalence of oxacillin and fluoroquinolone resistance. Res Microbiol. 2001,

21

(2001) Tankovic J. Single or double mutation alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Microb Drug Resist. 2001,

22

(2001) Siitonen A. Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia. Emerg Infect Dis. 2001,

23

(2001) Gutmann L. New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones. Antimicrob Agents Chemother. 2001,

24

(2001) Vila J. Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro. Int J Antimicrob Agents. 2001,

25

(2001) Towers GH. Antiviral and antimicrobial activities of Colombian medicinal plants. J Ethnopharmacol.. 2001,

26

(2001) Mount JR. Antimicrobial activity of essential oils from plants against selected pathogenic and saprophytic microorganisms. J Food Prot. 2001,

27

(2001) CC. Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis. Phytother Res. 2001,

28

(2000) Vuorela P. Antimicrobial activity of some coumarin containing herbal plants growing in Finland. J Ethnopharmacol. 2000,

29

(2000) Kanbara K et al. Antimicrobial and radical modulation activity of AV-07 a poly-herbal formula. In Vivo. 2000,

30

(2000) Yano I. Highly selective antibacterial activity of novel alkyl quinolone alkaloids form a Chinese herbal medicine against Helicobacter pylori in vitro. Microbiol Immunol. 2000,

31

(1999) El-Oqlah AA. Antimicrobial activity of extracts of herbal plants used in the traditional medicine of Jordan. J Ethnopharmacol.. 1999,

32

Antimicrobial activity of 63 medicinal plants. J Ethnopharmacol.. 1993,

33

Sebikali B. Rwandese herbal remedies used against gonorrhoea. J Ethnopharmacol. 1983,

34

Pachaly P. Pharmacological activities of water extracts of Umbelliferae plants. Arch Pharm Res. 1991,

  • 다운로드 수
  • 조회수
  • 0KCI 피인용수
  • 0WOS 피인용수

권호 내 다른 논문

추천 논문

상단으로 이동

대한한의학회지